Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 1/1998

01-03-1998

Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma

Authors: Mark M. Zalupski, Anthony F. Shields, Philip A. Philip, Michael Kraut, Patricia LoRusso, Lance K. Heilbrun, Vainutis Vaitkevicius

Published in: Investigational New Drugs | Issue 1/1998

Login to get access
Metadata
Title
Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma
Authors
Mark M. Zalupski
Anthony F. Shields
Philip A. Philip
Michael Kraut
Patricia LoRusso
Lance K. Heilbrun
Vainutis Vaitkevicius
Publication date
01-03-1998
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 1/1998
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1006087114621

Other articles of this Issue 1/1998

Investigational New Drugs 1/1998 Go to the issue

OriginalPaper

Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and Stage IV non-small cell lung cancer

OriginalPaper

Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies

OriginalPaper

A phase II study of Temozolomide in advanced untreated pancreatic cancer

Legacy

Progress and Promise

OriginalPaper

Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy

OriginalPaper

Vinflunine (20′,20′-difluoro- 3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits